|
JP2013532153A
(ja)
*
|
2010-06-18 |
2013-08-15 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド |
慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体
|
|
EP2734205B1
(en)
|
2011-07-21 |
2018-03-21 |
Tolero Pharmaceuticals, Inc. |
Heterocyclic protein kinase inhibitors
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US20150004175A1
(en)
*
|
2011-12-13 |
2015-01-01 |
Yale University |
Compositions and Methods for Reducing CTL Exhaustion
|
|
CA2860600C
(en)
|
2012-02-15 |
2022-07-26 |
F. Hoffmann-La Roche Ag |
Fc-receptor based affinity chromatography
|
|
EP2817327A1
(en)
*
|
2012-02-21 |
2014-12-31 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Tim receptors as virus entry cofactors
|
|
AU2013222185B2
(en)
*
|
2012-02-23 |
2018-07-26 |
Sloan-Kettering Institute For Cancer Research |
Prediction of responsiveness to treatment with immunomodulatory therapeutics and method of monitoring abscopal effects during such treatment
|
|
ES2704744T3
(es)
|
2012-06-13 |
2019-03-19 |
Incyte Holdings Corp |
Compuestos tricíclicos sustituidos como inhibidores de FGFR
|
|
CA2916638C
(en)
*
|
2012-07-31 |
2021-01-12 |
The Brigham And Women's Hospital, Inc. |
Modulation of the immune response
|
|
JP6457940B2
(ja)
|
2012-08-30 |
2019-01-23 |
アムジエン・インコーポレーテツド |
単純ヘルペスウイルスおよび免疫チェックポイント阻害薬を使用して、メラノーマを治療するための方法
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
CA2898100C
(en)
|
2013-01-14 |
2023-10-10 |
Xencor, Inc. |
Novel heterodimeric proteins
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
EP2948475A2
(en)
*
|
2013-01-23 |
2015-12-02 |
AbbVie Inc. |
Methods and compositions for modulating an immune response
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
EP2986306A4
(en)
|
2013-04-18 |
2016-12-07 |
Armo Biosciences Inc |
METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
|
|
EA035095B1
(ru)
|
2013-04-19 |
2020-04-27 |
Инсайт Холдингс Корпорейшн |
Бициклические гетероциклы в качестве ингибиторов fgfr
|
|
JP6742903B2
(ja)
|
2013-05-02 |
2020-08-19 |
アナプティスバイオ インコーポレイティッド |
プログラム死−１（ｐｄ−１）に対する抗体
|
|
ES2688206T3
(es)
|
2013-06-17 |
2018-10-31 |
Armo Biosciences, Inc. |
Procedimiento de evaluación de la identidad y la estabilidad de proteínas
|
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
|
CN105658232A
(zh)
|
2013-08-30 |
2016-06-08 |
阿尔莫生物科技股份有限公司 |
使用白细胞介素-10治疗疾病和病症的方法
|
|
US10570204B2
(en)
|
2013-09-26 |
2020-02-25 |
The Medical College Of Wisconsin, Inc. |
Methods for treating hematologic cancers
|
|
EP3068425B1
(en)
|
2013-11-11 |
2021-01-27 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
|
MY184154A
(en)
|
2013-12-12 |
2021-03-23 |
Shanghai hengrui pharmaceutical co ltd |
Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
|
|
ES2918501T3
(es)
|
2013-12-19 |
2022-07-18 |
Novartis Ag |
Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
|
|
CN103721255A
(zh)
*
|
2014-01-07 |
2014-04-16 |
苏州大学 |
共同阻断pd-1和tim-3信号通路在抗胃癌治疗中的用途
|
|
WO2015112534A2
(en)
*
|
2014-01-21 |
2015-07-30 |
Medimmune, Llc |
Compositions and methods for modulating and redirecting immune responses
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
SG10201900002QA
(en)
|
2014-01-24 |
2019-02-27 |
Dana Farber Cancer Institue Inc |
Antibody molecules to pd-1 and uses thereof
|
|
EP3099717B1
(en)
|
2014-01-31 |
2019-03-27 |
Novartis AG |
Antibody molecules to tim-3 and uses thereof
|
|
US20150259420A1
(en)
|
2014-03-14 |
2015-09-17 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
|
EP3593812A3
(en)
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor
|
|
AU2015244039B2
(en)
|
2014-04-07 |
2021-10-21 |
Novartis Ag |
Treatment of cancer using anti-CD19 chimeric antigen receptor
|
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
|
CA2958643A1
(en)
*
|
2014-07-07 |
2016-01-14 |
Dana Farber Cancer Institute, Inc. |
Methods of treating cancer
|
|
SG10201913765YA
(en)
|
2014-07-21 |
2020-03-30 |
Novartis Ag |
Treatment of cancer using a cd33 chimeric antigen receptor
|
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
WO2016014530A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
|
ES2781175T3
(es)
|
2014-07-31 |
2020-08-31 |
Novartis Ag |
Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
|
|
US9982052B2
(en)
|
2014-08-05 |
2018-05-29 |
MabQuest, SA |
Immunological reagents
|
|
WO2016020856A2
(en)
|
2014-08-05 |
2016-02-11 |
MabQuest SA |
Immunological reagents
|
|
CA2958200A1
(en)
|
2014-08-14 |
2016-02-18 |
Novartis Ag |
Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
|
|
ES2791248T3
(es)
|
2014-08-19 |
2020-11-03 |
Novartis Ag |
Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer
|
|
ES2771926T3
(es)
*
|
2014-09-13 |
2020-07-07 |
Novartis Ag |
Terapias de combinación
|
|
KR20250067191A
(ko)
|
2014-09-17 |
2025-05-14 |
노파르티스 아게 |
입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
|
|
KR20170068504A
(ko)
|
2014-10-08 |
2017-06-19 |
노파르티스 아게 |
키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도
|
|
JP6991857B2
(ja)
|
2014-10-10 |
2022-01-13 |
イデラ ファーマシューティカルズ インコーポレイテッド |
Ｔｌｒ９アゴニストをチェックポイント阻害剤と共に用いるがんの治療
|
|
TWI716362B
(zh)
|
2014-10-14 |
2021-01-21 |
瑞士商諾華公司 |
針對ｐｄ－ｌ１之抗體分子及其用途
|
|
WO2016061456A2
(en)
|
2014-10-17 |
2016-04-21 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for identification, assessment, prevention, and treatment of t-cell exhaustion using cd39 biomarkers and modulators
|
|
GB201419094D0
(en)
*
|
2014-10-27 |
2014-12-10 |
Agency Science Tech & Res |
Anti-TIM-3-antibodies
|
|
GB201419084D0
(en)
*
|
2014-10-27 |
2014-12-10 |
Agency Science Tech & Res |
Anti-PD-1 antibodies
|
|
US10259874B2
(en)
|
2014-10-27 |
2019-04-16 |
Agency For Science, Technology And Research |
Anti-TIM-3 antibodies
|
|
RS59340B1
(sr)
|
2014-11-06 |
2019-10-31 |
Hoffmann La Roche |
Varijante fc regiona sa modifikovanim vezivanjem za fcrn i metode upotrebe
|
|
DK3220927T3
(en)
|
2014-11-20 |
2022-02-14 |
Promega Corp |
Systems and methods for assessing modulators of immune checkpoints
|
|
DK3221355T3
(da)
|
2014-11-20 |
2020-12-07 |
Hoffmann La Roche |
Kombinationsbehandling med T-celleaktiverende bispecifikke antigenbindende molekyler CD3 og folatreceptor 1 (FolR1) samt PD-1-aksebindende antagonister
|
|
BR112017011166A2
(pt)
|
2014-11-26 |
2018-02-27 |
Xencor, Inc. |
anticorpos heterodiméricos que se ligam a cd3 e cd38
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
CN110894240B
(zh)
|
2014-11-26 |
2022-04-15 |
森科股份有限公司 |
结合cd3和肿瘤抗原的异二聚体抗体
|
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
|
ES2948037T3
(es)
|
2014-12-18 |
2023-08-30 |
Amgen Inc |
Formulación estable congelada del virus del herpes simple
|
|
WO2016105450A2
(en)
|
2014-12-22 |
2016-06-30 |
Xencor, Inc. |
Trispecific antibodies
|
|
HK1247861A1
(zh)
|
2015-01-30 |
2018-10-05 |
President And Fellows Of Harvard College |
用於癌症治疗的肿瘤周围和肿瘤内部材料
|
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
MX373169B
(es)
|
2015-02-20 |
2020-04-24 |
Incyte Holdings Corp |
Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
|
|
CA2978892A1
(en)
|
2015-03-06 |
2016-09-15 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind tim3
|
|
EA201792184A1
(ru)
*
|
2015-04-01 |
2018-04-30 |
Анаптисбайо, Инк. |
Антитела, направленные против т-клеточного иммуноглобулина и белка муцина 3 (tim-3)
|
|
US20180140602A1
(en)
|
2015-04-07 |
2018-05-24 |
Novartis Ag |
Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
|
|
WO2016164799A1
(en)
*
|
2015-04-10 |
2016-10-13 |
The Regents Of The University Of California |
Methods of determining patient populations amenable to immunomodulatory treatment of cancer
|
|
SG11201708516YA
(en)
|
2015-04-17 |
2017-11-29 |
David Maxwell Barrett |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
WO2016171722A1
(en)
*
|
2015-04-24 |
2016-10-27 |
The Brigham And Women's Hospital, Inc. |
Interactions between ceacam and tim family members
|
|
ES2739749T3
(es)
|
2015-05-18 |
2020-02-03 |
Tolero Pharmaceuticals Inc |
Profármacos de alvocidib que tienen biodisponibilidad aumentada
|
|
CA2986755A1
(en)
|
2015-05-28 |
2016-12-01 |
Armo Biosciences, Inc. |
Pegylated interleukin-10 for use in treating cancer
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
TWI870335B
(zh)
*
|
2015-06-12 |
2025-01-21 |
美商宏觀基因股份有限公司 |
變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用
|
|
EP3316888A1
(en)
|
2015-07-02 |
2018-05-09 |
Celgene Corporation |
Combination therapy for treatment of hematological cancers and solid tumors
|
|
CN114591433A
(zh)
|
2015-07-13 |
2022-06-07 |
西托姆克斯治疗公司 |
抗pd-1抗体、可活化抗pd-1抗体及其使用方法
|
|
IL274572B2
(en)
|
2015-07-16 |
2024-01-01 |
Biolinerx Ltd |
Compositions and methods for treating cancer
|
|
AU2016297014B2
(en)
|
2015-07-21 |
2021-06-17 |
Novartis Ag |
Methods for improving the efficacy and expansion of immune cells
|
|
DK3317301T3
(da)
|
2015-07-29 |
2021-06-28 |
Immutep Sas |
Kombinationsterapier omfattende antistofmolekyler mod lag-3
|
|
WO2017019846A1
(en)
|
2015-07-30 |
2017-02-02 |
Macrogenics, Inc. |
Pd-1-binding molecules and methods use thereof
|
|
JO3620B1
(ar)
*
|
2015-08-05 |
2020-08-27 |
Amgen Res Munich Gmbh |
مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
|
|
EP3337826A1
(en)
|
2015-08-20 |
2018-06-27 |
Sutro Biopharma, Inc. |
Anti-tim-3 antibodies, compositions comprising anti-tim-3 antibodies and methods of making and using anti-tim-3 antibodies
|
|
US10398761B2
(en)
|
2015-08-25 |
2019-09-03 |
Armo Biosciences, Inc. |
Methods of using combinations of PEG-IL-10 and IL-15 for treating cancers
|
|
WO2017032867A1
(en)
|
2015-08-27 |
2017-03-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of patients suffering from a lung cancer
|
|
CN114605548A
(zh)
|
2015-09-01 |
2022-06-10 |
艾吉纳斯公司 |
抗-pd-1抗体及其使用方法
|
|
JP6905163B2
(ja)
|
2015-09-03 |
2021-07-21 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
サイトカイン放出症候群を予測するバイオマーカー
|
|
WO2017055327A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of endothelial cells in a tissue sample
|
|
WO2017055321A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of fibroblasts in a tissue sample
|
|
WO2017055324A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of cells of monocytic origin in a tissue sample
|
|
WO2017055325A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of nk cells in a tissue sample
|
|
WO2017055319A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of b cells in a tissue sample
|
|
WO2017055322A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of neutrophils in a tissue sample
|
|
WO2017055326A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of myeloid dendritic cells in a tissue sample
|
|
WO2017055320A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of cytotoxic lymphocytes in a tissue sample
|
|
EP3355875B1
(en)
|
2015-10-01 |
2021-09-29 |
Gilead Sciences, Inc. |
Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers
|
|
NZ739090A
(en)
*
|
2015-10-02 |
2025-06-27 |
Hoffmann La Roche |
Bispecific antibodies specific for pd1 and tim3
|
|
WO2017055393A1
(en)
*
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
|
|
US12030942B2
(en)
|
2015-10-02 |
2024-07-09 |
Les Laboratoires Servier |
Anti-PD-1 antibodies and compositions
|
|
PL3368572T3
(pl)
*
|
2015-10-02 |
2022-09-12 |
Symphogen A/S |
Przeciwciała anty-PD-1 oraz kompozycje
|
|
WO2017060397A1
(en)
|
2015-10-09 |
2017-04-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of subjects suffering from melanoma metastases
|
|
US11207393B2
(en)
*
|
2015-10-16 |
2021-12-28 |
President And Fellows Of Harvard College |
Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
|
|
EP3370768B9
(en)
|
2015-11-03 |
2022-03-16 |
Janssen Biotech, Inc. |
Antibodies specifically binding pd-1 and their uses
|
|
JP7058219B2
(ja)
|
2015-12-07 |
2022-04-21 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｐｓｍａに結合するヘテロ二量体抗体
|
|
US10954301B2
(en)
|
2015-12-14 |
2021-03-23 |
Macrogenics, Inc. |
Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
|
|
ES2916874T3
(es)
|
2015-12-17 |
2022-07-06 |
Incyte Corp |
Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1
|
|
WO2017106630A1
(en)
|
2015-12-18 |
2017-06-22 |
The General Hospital Corporation |
Polyacetal polymers, conjugates, particles and uses thereof
|
|
JP7126941B2
(ja)
|
2015-12-22 |
2022-08-29 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
がんを治療するための抗ｐｄ－１抗体と二重特異性抗ｃｄ２０／抗ｃｄ３抗体の組合せ
|
|
AU2016379372A1
(en)
|
2015-12-22 |
2018-08-02 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
EP3393504B1
(en)
|
2015-12-22 |
2025-09-24 |
Novartis AG |
Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
|
|
WO2017118634A1
(en)
|
2016-01-04 |
2017-07-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of pd-1 and tim-3 as a measure for cd8+ cells in predicting and treating renal cell carcinoma
|
|
CN108430473B
(zh)
|
2016-01-08 |
2021-08-31 |
细胞基因公司 |
抗增殖化合物以及其药物组合物和用途
|
|
EP3399981B1
(en)
|
2016-01-08 |
2023-08-02 |
Celgene Corporation |
Solid forms of 2-(4-chlorophenyl)-n-((2-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
|
|
WO2017120437A1
(en)
|
2016-01-08 |
2017-07-13 |
Celgene Corporation |
Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
|
|
WO2017125815A2
(en)
|
2016-01-22 |
2017-07-27 |
MabQuest SA |
Immunological reagents
|
|
US11214617B2
(en)
|
2016-01-22 |
2022-01-04 |
MabQuest SA |
Immunological reagents
|
|
WO2017129790A1
(en)
|
2016-01-28 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of cancer
|
|
WO2017129763A1
(en)
|
2016-01-28 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
|
|
JP6902040B2
(ja)
|
2016-01-28 |
2021-07-14 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
免疫チェックポイント阻害剤の効力を増強する方法
|
|
US20230183346A1
(en)
|
2016-02-26 |
2023-06-15 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Antibodies having specificity for btla and uses thereof
|
|
AU2017225733A1
(en)
|
2016-03-04 |
2018-09-27 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
|
|
CN109310885B
(zh)
|
2016-03-15 |
2022-05-31 |
梅尔莎纳医疗公司 |
NaPi2b靶向抗体-药物缀合物及其使用方法
|
|
WO2017180385A1
(en)
|
2016-04-12 |
2017-10-19 |
Eli Lilly And Company |
Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer
|
|
TN2018000333A1
(en)
|
2016-04-12 |
2020-01-16 |
Symphogen As |
Anti-tim-3 antibodies and compositions
|
|
EP4014967A1
(en)
|
2016-04-29 |
2022-06-22 |
Icahn School of Medicine at Mount Sinai |
Targeting the innate immunesystem to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis
|
|
AR108377A1
(es)
|
2016-05-06 |
2018-08-15 |
Medimmune Llc |
Proteínas de unión biespecíficas y sus usos
|
|
TWI755395B
(zh)
|
2016-05-13 |
2022-02-21 |
美商再生元醫藥公司 |
抗-pd-1抗體與輻射治療癌症之組合
|
|
MA45025A
(fr)
*
|
2016-05-20 |
2019-03-27 |
Lilly Co Eli |
Traitement d'association utilisant des inhibiteurs de notch et de pd-1 ou pd-l1
|
|
EP3463452A1
(en)
|
2016-05-24 |
2019-04-10 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd)
|
|
CN109689089A
(zh)
|
2016-05-25 |
2019-04-26 |
国家医疗保健研究所 |
治疗癌症的方法和组合物
|
|
TWI781934B
(zh)
|
2016-05-27 |
2022-11-01 |
美商艾吉納斯公司 |
抗-tim-3抗體及其使用方法
|
|
MX2018014950A
(es)
*
|
2016-06-07 |
2019-04-25 |
Macrogenics Inc |
Terapia de combinacion.
|
|
JP7185530B2
(ja)
|
2016-06-13 |
2022-12-07 |
トルク セラピューティクス， インコーポレイテッド |
免疫細胞機能を促進するための方法および組成物
|
|
SI3468586T1
(sl)
|
2016-06-14 |
2025-01-31 |
Xencor, Inc. |
Bispecifična protitelesa za zaviralce kontrolnih točk
|
|
BR112018076534A2
(pt)
|
2016-06-20 |
2019-04-02 |
Incyte Corporation |
compostos heterocíclicos como imunomoduladores
|
|
RU2754507C2
(ru)
|
2016-06-24 |
2021-09-02 |
Инфинити Фармасьютикалз, Инк. |
Комбинированная терапия
|
|
WO2018005706A1
(en)
|
2016-06-28 |
2018-01-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
|
RU2021127872A
(ru)
|
2016-06-30 |
2021-11-09 |
Онкорус, Инк. |
Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов
|
|
WO2018011166A2
(en)
|
2016-07-12 |
2018-01-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of myeloid dendritic cells in a tissue sample
|
|
MY200602A
(en)
|
2016-07-14 |
2024-01-04 |
Bristol Myers Squibb Co |
Antibodies against tim3 and uses thereof
|
|
EP3487878A4
(en)
|
2016-07-20 |
2020-03-25 |
University of Utah Research Foundation |
CD229-CAR-T CELLS AND METHOD FOR USE THEREOF
|
|
WO2018023113A1
(en)
*
|
2016-07-29 |
2018-02-01 |
New York University |
Treating solid tumor by targeting dectin-1 signaling
|
|
WO2018029336A1
(en)
|
2016-08-12 |
2018-02-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway.
|
|
PT3500299T
(pt)
|
2016-08-19 |
2024-02-21 |
Beigene Switzerland Gmbh |
Combinação de zanubrutinib com um anticorpo anti-cd20 ou anti-pd-1 para utilização no tratamento do cancro
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
WO2018046736A1
(en)
|
2016-09-12 |
2018-03-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of patients suffering from cancer
|
|
WO2018046738A1
(en)
|
2016-09-12 |
2018-03-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of patients suffering from cancer
|
|
EP3515453A1
(en)
|
2016-09-22 |
2019-07-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for reprograming immune environment in a subject in need thereof
|
|
US20190225701A1
(en)
*
|
2016-09-26 |
2019-07-25 |
The Brigham And Women's Hospital, Inc. |
Regulators of b cell-mediated immunosuppression
|
|
EP3523331A1
(en)
|
2016-10-07 |
2019-08-14 |
Novartis AG |
Chimeric antigen receptors for the treatment of cancer
|
|
CN110214147A
(zh)
|
2016-10-14 |
2019-09-06 |
Xencor股份有限公司 |
IL15/IL15Rα异源二聚体FC-融合蛋白
|
|
WO2018075447A1
(en)
|
2016-10-19 |
2018-04-26 |
The Trustees Of Columbia University In The City Of New York |
Combination of braf inhibitor, talimogene laherparepvec, and immune checkpoint inhibitor for use in the treatment cancer (melanoma)
|
|
SG11201903867YA
(en)
|
2016-11-01 |
2019-05-30 |
Anaptysbio Inc |
Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
|
|
CA3041684C
(en)
|
2016-11-01 |
2023-09-26 |
Anaptysbio, Inc. |
Antibodies directed against programmed death- 1 (pd-1)
|
|
WO2018087391A1
(en)
|
2016-11-14 |
2018-05-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for modulating stem cells proliferation or differentiation
|
|
WO2018094275A1
(en)
|
2016-11-18 |
2018-05-24 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
|
TWI780083B
(zh)
|
2016-11-18 |
2022-10-11 |
丹麥商賽門弗鎮公司 |
抗pd-1抗體及組成物
|
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
|
AU2017368332A1
(en)
|
2016-12-03 |
2019-06-13 |
Juno Therapeutics, Inc. |
Methods for modulation of CAR-T cells
|
|
WO2018106738A1
(en)
|
2016-12-05 |
2018-06-14 |
Massachusetts Institute Of Technology |
Brush-arm star polymers, conjugates and particles, and uses thereof
|
|
JP7106538B2
(ja)
|
2016-12-07 |
2022-07-26 |
アジェナス インコーポレイテッド |
抗体およびその使用方法
|
|
WO2018106699A1
(en)
*
|
2016-12-08 |
2018-06-14 |
Nantbio, Inc. |
Method of validating the triggering of an immune response to a neoepitope of a tumor with t-cells
|
|
EP3551659A1
(en)
*
|
2016-12-08 |
2019-10-16 |
Eli Lilly and Company |
Anti-tim-3 antibodies for combination with anti-pd-l1 antibodies
|
|
JOP20190133A1
(ar)
*
|
2016-12-08 |
2019-06-02 |
Innovent Biologics Suzhou Co Ltd |
أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1
|
|
WO2018119286A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Bicyclic heteroaromatic compounds as immunomodulators
|
|
AU2017382870B2
(en)
|
2016-12-22 |
2022-03-24 |
Incyte Corporation |
Benzooxazole derivatives as immunomodulators
|
|
JP2020501589A
(ja)
|
2016-12-23 |
2020-01-23 |
ウイルツ・バイオロジクス・リミテッド |
がんの治療
|
|
WO2018122249A1
(en)
|
2016-12-28 |
2018-07-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of patients suffering from a microsatellite stable colorectal cancer
|
|
WO2018122245A1
(en)
|
2016-12-28 |
2018-07-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of predicting the survival time of patients suffering from cms3 colorectal cancer
|
|
MX2019008208A
(es)
|
2017-01-09 |
2019-12-11 |
Tesaro Inc |
Métodos para tratar el cáncer con anticuerpos anti-tim-3.
|
|
PT3565844T
(pt)
|
2017-01-09 |
2023-05-02 |
Tesaro Inc |
Métodos de tratamento de cancro com anticorpos anti-pd-1
|
|
US12473343B2
(en)
|
2017-01-10 |
2025-11-18 |
The General Hospital Corporation |
Targeted t cells with cytotoxicity toward immunosuppressive cells
|
|
US11566077B2
(en)
*
|
2017-01-17 |
2023-01-31 |
The University Of Chicago |
Dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment
|
|
US10434095B2
(en)
|
2017-01-27 |
2019-10-08 |
Celgene Corporation |
3-(1-oxo-4-((4-((3-oxomorpholino)methyl)benzyl)oxy)isoindolin-2-yl)piperidine-2,6-dione and isotopologues thereof
|
|
WO2018146148A1
(en)
|
2017-02-07 |
2018-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
A method for predicting the response to checkpoint blockade cancer immunotherapy
|
|
WO2018146128A1
(en)
|
2017-02-07 |
2018-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Detection of kit polymorphism for predicting the response to checkpoint blockade cancer immunotherapy
|
|
KR20240011262A
(ko)
|
2017-02-21 |
2024-01-25 |
리제너론 파아마슈티컬스, 인크. |
폐암의 치료를 위한 항-pd-1 항체
|
|
WO2018156777A1
(en)
*
|
2017-02-22 |
2018-08-30 |
Sutro Biopharma, Inc. |
Pd-1/tim-3 bi-specific antibodies, compositions thereof, and methods of making and using the same
|
|
EP3587452A4
(en)
|
2017-02-27 |
2021-03-03 |
Jiangsu Hengrui Medicine Co., Ltd. |
ANTI-TIM-3 ANTIBODIES, ANTIGEN BINDING FRAGMENT OF IT, AND MEDICAL USES OF IT
|
|
TW201834697A
(zh)
|
2017-02-28 |
2018-10-01 |
美商梅爾莎納醫療公司 |
Her2標靶抗體－藥物結合物之組合療法
|
|
WO2018167778A1
(en)
|
2017-03-12 |
2018-09-20 |
Yeda Research And Development Co. Ltd. |
Methods of diagnosing and prognosing cancer
|
|
WO2018167780A1
(en)
|
2017-03-12 |
2018-09-20 |
Yeda Research And Development Co. Ltd. |
Methods of prognosing and treating cancer
|
|
JP2020510050A
(ja)
|
2017-03-15 |
2020-04-02 |
アムジエン・インコーポレーテツド |
がんを治療するための、腫瘍溶解性ウイルスの単独又はチェックポイント阻害剤との組み合わせでの使用
|
|
JP7148539B2
(ja)
*
|
2017-04-03 |
2022-10-05 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
免疫抱合体
|
|
RU2761377C2
(ru)
|
2017-04-03 |
2021-12-07 |
Ф. Хоффманн-Ля Рош Аг |
Иммуноконъюгаты антитела к pd-1 с мутантом il-2 или с il-15
|
|
TWI690538B
(zh)
|
2017-04-05 |
2020-04-11 |
瑞士商赫孚孟拉羅股份公司 |
特異性結合至pd1至lag3的雙特異性抗體
|
|
EA201992350A1
(ru)
*
|
2017-04-05 |
2020-03-23 |
Симфоген А/С |
Комбинированные лекарственные средства, нацеленные на pd-1, tim-3 и lag-3
|
|
US12310999B2
(en)
|
2017-04-28 |
2025-05-27 |
Merck Sharp & Dohme Corp. |
Biomarkers for cancer therapeutics
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
WO2018201056A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
EP3615068A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
AU2018275894B2
(en)
|
2017-06-02 |
2025-04-24 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods for treatment using adoptive cell therapy
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
WO2018234367A1
(en)
|
2017-06-20 |
2018-12-27 |
Institut Curie |
SUV39H1 HISTONE METHYLTRANSFERASE INHIBITOR FOR USE IN ANTICANCER POLYTHERAPY
|
|
EP3641772B1
(en)
|
2017-06-22 |
2023-08-02 |
Celgene Corporation |
Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
|
|
WO2018235056A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
Il-1beta binding antibodies for use in treating cancer
|
|
JP2020524694A
(ja)
|
2017-06-22 |
2020-08-20 |
ノバルティス アーゲー |
がんの処置における使用のためのＩＬ−１β結合性抗体
|
|
WO2018237173A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
CN118307674A
(zh)
|
2017-06-22 |
2024-07-09 |
诺华股份有限公司 |
针对cd73的抗体分子及其用途
|
|
AU2018292618A1
(en)
|
2017-06-27 |
2019-12-19 |
Novartis Ag |
Dosage regimens for anti-TIM-3 antibodies and uses thereof
|
|
EP3644721A1
(en)
|
2017-06-29 |
2020-05-06 |
Juno Therapeutics, Inc. |
Mouse model for assessing toxicities associated with immunotherapies
|
|
EP4201399A3
(en)
|
2017-06-30 |
2023-08-09 |
Celgene Corporation |
Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide
|
|
EP3649155A1
(en)
*
|
2017-07-06 |
2020-05-13 |
Merus N.V. |
Bispecific anti pd1-anti tim3 antibodies
|
|
TWI791552B
(zh)
|
2017-07-10 |
2023-02-11 |
美商西建公司 |
抗增生化合物及其使用方法
|
|
CN111163798A
(zh)
|
2017-07-20 |
2020-05-15 |
诺华股份有限公司 |
用于抗lag-3抗体的给药方案及其用途
|
|
US11926664B2
(en)
|
2017-07-25 |
2024-03-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for modulating monocytopoiesis
|
|
CA3070295A1
(en)
|
2017-07-28 |
2019-01-31 |
Phanes Therapeutics, Inc. |
Anti-tim-3 antibodies and uses thereof
|
|
SG11202000198QA
(en)
|
2017-08-04 |
2020-02-27 |
Genmab As |
Binding agents binding to pd-l1 and cd137 and use thereof
|
|
EP3676616A1
(en)
|
2017-08-28 |
2020-07-08 |
Bristol-Myers Squibb Company |
Tim-3 antagonists for the treatment and diagnosis of cancers
|
|
WO2019055579A1
(en)
|
2017-09-12 |
2019-03-21 |
Tolero Pharmaceuticals, Inc. |
TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
|
|
WO2019057744A1
(en)
|
2017-09-19 |
2019-03-28 |
Institut Curie |
AROMATIC HYDROCARBON RECEPTOR AGONIST FOR USE IN ASSOCIATION TREATMENT AGAINST CANCER
|
|
EP3700933A1
(en)
|
2017-10-25 |
2020-09-02 |
Novartis AG |
Antibodies targeting cd32b and methods of use thereof
|
|
IL312910B1
(en)
|
2017-10-27 |
2026-02-01 |
Univ New York |
Anti-galectin-9 antibodies and their uses
|
|
AU2018358067A1
(en)
|
2017-11-01 |
2020-05-07 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for B-cell maturation antigen
|
|
JP7447006B2
(ja)
|
2017-11-01 |
2024-03-11 |
ジュノー セラピューティクス インコーポレイテッド |
Ｂ細胞成熟抗原（ｂｃｍａ）に特異的なキメラ抗原受容体
|
|
WO2019089858A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
|
SG11202003427XA
(en)
|
2017-11-06 |
2020-05-28 |
Juno Therapeutics Inc |
Combination of a cell therapy and a gamma secretase inhibitor
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
JP2021502100A
(ja)
|
2017-11-08 |
2021-01-28 |
ゼンコア インコーポレイテッド |
新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体
|
|
CA3079844A1
(en)
|
2017-11-10 |
2019-05-16 |
Armo Biosciences, Inc. |
Compositions and methods of use of interleukin-10 in combination with immune checkpoint pathway inhibitors
|
|
TW201922291A
(zh)
|
2017-11-16 |
2019-06-16 |
瑞士商諾華公司 |
組合療法
|
|
KR20250008153A
(ko)
|
2017-11-24 |
2025-01-14 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
암 치료를 위한 방법 및 조성물
|
|
EP3717021A1
(en)
|
2017-11-27 |
2020-10-07 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
|
BR112020010579A2
(pt)
|
2017-11-30 |
2020-11-10 |
Novartis Ag |
receptor de antígeno quimérico de alvejamento de bcma e usos do mesmo
|
|
WO2019118937A1
(en)
|
2017-12-15 |
2019-06-20 |
Juno Therapeutics, Inc. |
Anti-cct5 binding molecules and methods of use thereof
|
|
US11319355B2
(en)
|
2017-12-19 |
2022-05-03 |
Xencor, Inc. |
Engineered IL-2 Fc fusion proteins
|
|
EP3727463A1
(en)
|
2017-12-21 |
2020-10-28 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
|
MX2020006808A
(es)
|
2017-12-28 |
2020-12-11 |
Massachusetts Gen Hospital |
Ubicar al complejo de signalosoma cbm induce a las celulas t reguladoras inflamar al microambiente tumoral.
|
|
US11865081B2
(en)
|
2017-12-29 |
2024-01-09 |
Virogin Biotech Canada Ltd. |
Oncolytic viral delivery of therapeutic polypeptides
|
|
TW201930591A
(zh)
|
2018-01-08 |
2019-08-01 |
瑞士商諾華公司 |
用於與嵌合抗原受體療法併用之免疫增強rna
|
|
US20210363242A1
(en)
|
2018-01-16 |
2021-11-25 |
Bristol-Myers Squibb Company |
Methods of treating cancer with antibodies against tim3
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
JP7383620B2
(ja)
|
2018-01-31 |
2023-11-20 |
セルジーン コーポレイション |
養子細胞療法およびチェックポイント阻害剤を使用する併用療法
|
|
EP3746116A1
(en)
|
2018-01-31 |
2020-12-09 |
Novartis AG |
Combination therapy using a chimeric antigen receptor
|
|
WO2019160956A1
(en)
|
2018-02-13 |
2019-08-22 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
BR122023024273A2
(pt)
|
2018-02-27 |
2024-02-20 |
Incyte Corporation |
Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos
|
|
CA3090620A1
(en)
|
2018-03-06 |
2019-09-12 |
Institut Curie |
Inhibitor of setdb1 histone methyltransferase for use in cancer combination therapy
|
|
PE20210665A1
(es)
|
2018-03-23 |
2021-03-31 |
Bristol Myers Squibb Co |
Anticuerpos contra mica y/o micb y sus usos
|
|
WO2019185792A1
(en)
|
2018-03-29 |
2019-10-03 |
Philogen S.P.A |
Cancer treatment using immunoconjugates and immune check-point inhibitors
|
|
CR20200520A
(es)
|
2018-03-30 |
2021-03-09 |
Incyte Corp |
Compuestos heterocíclicos como inmunomoduladores
|
|
WO2019195623A2
(en)
|
2018-04-04 |
2019-10-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
|
US11505595B2
(en)
|
2018-04-18 |
2022-11-22 |
Xencor, Inc. |
TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
|
|
SG11202010163QA
(en)
|
2018-04-18 |
2020-11-27 |
Xencor Inc |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
|
WO2019207030A1
(en)
|
2018-04-26 |
2019-10-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer
|
|
EP3784351A1
(en)
|
2018-04-27 |
2021-03-03 |
Novartis AG |
Car t cell therapies with enhanced efficacy
|
|
US20210396739A1
(en)
|
2018-05-01 |
2021-12-23 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
CR20200590A
(es)
|
2018-05-04 |
2021-04-26 |
Incyte Corp |
Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
|
|
MA52493A
(fr)
|
2018-05-04 |
2021-03-10 |
Incyte Corp |
Sels d'un inhibiteur de fgfr
|
|
WO2019217821A1
(en)
|
2018-05-11 |
2019-11-14 |
Incyte Corporation |
Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
|
|
WO2019222677A1
(en)
|
2018-05-18 |
2019-11-21 |
Incyte Corporation |
Fused pyrimidine derivatives as a2a / a2b inhibitors
|
|
EA202092830A1
(ru)
|
2018-05-23 |
2021-04-08 |
Селджин Корпорейшн |
Антипролиферативные соединения и биспецифические антитела к bcma и cd3 для комбинированного применения
|
|
BR112020023756A2
(pt)
|
2018-05-23 |
2021-02-09 |
Celgene Corporation |
tratamento de mieloma múltiplo e uso de biomarcadores para 4-(4-(4-(((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-4-il)oxi)metil)benzil)piperazin-1-il)-3-fluorobenzonitrila
|
|
AR126019A1
(es)
|
2018-05-30 |
2023-09-06 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
UY38251A
(es)
|
2018-06-01 |
2019-12-31 |
Novartis Ag |
Moléculas de unión contra bcma y usos de las mismas
|
|
CA3100724A1
(en)
|
2018-06-13 |
2019-12-19 |
Novartis Ag |
B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
|
|
CN112533629A
(zh)
|
2018-06-19 |
2021-03-19 |
阿尔莫生物科技股份有限公司 |
结合使用il-10药剂与嵌合抗原受体细胞疗法的组合物和方法
|
|
CN111902428B
(zh)
*
|
2018-07-03 |
2023-11-10 |
上海健信生物医药科技有限公司 |
一种双特异性抗体及其用途
|
|
GEP20237548B
(en)
|
2018-07-05 |
2023-10-10 |
Incyte Corp |
Fused pyrazine derivatives as a2a /a2b inhibitors
|
|
DK3820573T3
(da)
|
2018-07-10 |
2023-10-23 |
Novartis Ag |
3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidin-2,6-dion-derivativer og anvendelse deraf ved behandling af ikaros family zinc finger 2 (ikzf2)-afhængige sygdomme
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
|
WO2020030634A1
(en)
|
2018-08-06 |
2020-02-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cancers
|
|
BR112021002096A2
(pt)
|
2018-08-20 |
2021-06-01 |
Jiangsu Hengrui Medicine Co., Ltd. |
uso de anticorpos tim-3 na preparação de medicamentos para o tratamento de tumores
|
|
CN112543647B
(zh)
|
2018-08-28 |
2024-04-16 |
江苏恒瑞医药股份有限公司 |
一种tim3抗体药物组合物及其用途
|
|
EP3856779A1
(en)
|
2018-09-28 |
2021-08-04 |
Novartis AG |
Cd22 chimeric antigen receptor (car) therapies
|
|
WO2020069409A1
(en)
|
2018-09-28 |
2020-04-02 |
Novartis Ag |
Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
|
|
WO2020070062A1
(en)
|
2018-10-01 |
2020-04-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of tim-3 inhibitors for the treatment of exacerbations in patients suffering from severe asthma
|
|
EP3861016A2
(en)
|
2018-10-03 |
2021-08-11 |
Xencor, Inc. |
Il-12 heterodimeric fc-fusion proteins
|
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
|
WO2020079692A1
(en)
|
2018-10-17 |
2020-04-23 |
Biolinerx Ltd. |
Treatment of metastatic pancreatic adenocarcinoma
|
|
US20210340240A1
(en)
|
2018-10-18 |
2021-11-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Combination of a big-h3 antagonist and an immune checkpoint inhibitor for the treatment of solid tumor
|
|
AU2019369340A1
(en)
|
2018-10-29 |
2021-05-20 |
Mersana Therapeutics, Inc. |
Cysteine engineered antibody-drug conjugates with peptide-containing linkers
|
|
MA54079A
(fr)
|
2018-11-01 |
2021-09-08 |
Juno Therapeutics Inc |
Récepteurs antigéniques chimériques spécifiques du gprc5d (élément d du groupe 5 de classe c des récepteurs couplés à la protéine g)
|
|
KR20210113169A
(ko)
|
2018-11-01 |
2021-09-15 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Β세포 성숙 항원에 특이적인 키메라 항원 수용체를 이용한 치료 방법
|
|
HUE067601T2
(hu)
|
2018-11-14 |
2024-10-28 |
Regeneron Pharma |
PD-1 inhibitorok intraléziós beadása a bõrrák kezelésére
|
|
KR20210104713A
(ko)
|
2018-11-16 |
2021-08-25 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Ｂ 세포 악성 종양 치료를 위한 조작된 ｔ 세포 투약 방법
|
|
AU2019387218A1
(en)
|
2018-11-26 |
2021-06-03 |
Massachusetts Institute Of Technology |
Compositions and methods for immune tolerance
|
|
PL3886875T3
(pl)
|
2018-11-30 |
2024-09-09 |
Juno Therapeutics, Inc. |
Metody leczenia z wykorzystaniem adoptywnej terapii komórkowej
|
|
IL283522B2
(en)
|
2018-12-03 |
2025-03-01 |
Agensys Inc |
Pharmaceutical compositions containing anti-191P4D12 antibody drug conjugates and methods of using them
|
|
US11034710B2
(en)
|
2018-12-04 |
2021-06-15 |
Sumitomo Dainippon Pharma Oncology, Inc. |
CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
|
|
MX2021007391A
(es)
|
2018-12-20 |
2021-09-23 |
Novartis Ag |
Regimenes de baja dosis extendida para inhibidores de mdm2.
|
|
KR20210106437A
(ko)
|
2018-12-20 |
2021-08-30 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
|
|
BR112021011351A2
(pt)
|
2018-12-21 |
2021-11-16 |
Novartis Ag |
Uso de anticorpos il-1 beta no tratamento ou prevenção de síndrome mielodisplásica
|
|
WO2020127965A1
(en)
|
2018-12-21 |
2020-06-25 |
Onxeo |
New conjugated nucleic acid molecules and their uses
|
|
EP3897613A1
(en)
|
2018-12-21 |
2021-10-27 |
Novartis AG |
Use of il-1beta binding antibodies
|
|
CN113227138A
(zh)
|
2018-12-21 |
2021-08-06 |
诺华股份有限公司 |
IL-1β结合抗体的用途
|
|
WO2020128637A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1 binding antibodies in the treatment of a msi-h cancer
|
|
CA3124690A1
(en)
|
2018-12-27 |
2020-07-02 |
Amgen Inc. |
Lyophilized virus formulations
|
|
EP3906415B1
(en)
|
2019-01-03 |
2026-04-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer
|
|
WO2020146440A1
(en)
|
2019-01-09 |
2020-07-16 |
Celgene Corporation |
Antiproliferative compounds and second active agents for use in treating multiple myeloma
|
|
AU2020206692B2
(en)
|
2019-01-09 |
2025-03-27 |
Celgene Corporation |
Pharmaceutical compositions comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same
|
|
RS67646B1
(sr)
|
2019-01-09 |
2026-02-27 |
Celgene Corp |
Čvrsti oblici koji obuhvataju (s)-4-(4-(4-(((2-(2,6-dioksopiperidin-3-il)-1-oksoizoindolin-4-il)oksi)metil) benzil)piperazin-1-il)-3-fluorobenzonitril i soli istog, kao i kompozicije koje obuhvataju i metode korišćenja istih
|
|
CA3123303A1
(en)
|
2019-01-29 |
2020-08-06 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
|
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
|
NZ778055A
(en)
|
2019-02-12 |
2025-11-28 |
Sumitomo Pharma America Inc |
Formulations comprising heterocyclic protein kinase inhibitors
|
|
WO2020168197A1
(en)
|
2019-02-15 |
2020-08-20 |
Incyte Corporation |
Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
|
|
US20200316064A1
(en)
|
2019-02-15 |
2020-10-08 |
Incyte Corporation |
Cyclin-dependent kinase 2 biomarkers and uses thereof
|
|
EP3924055B1
(en)
|
2019-02-15 |
2024-04-03 |
Novartis AG |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
CN113490528B
(zh)
|
2019-02-15 |
2024-12-03 |
诺华股份有限公司 |
3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
|
UA128825C2
(uk)
|
2019-03-01 |
2024-10-30 |
Ксенкор, Інк. |
Гетеродимерні антитіла, що зв'язують enpp3 та cd3
|
|
AU2020232264B2
(en)
|
2019-03-05 |
2026-02-19 |
Amgen Inc. |
Use of oncolytic viruses for the treatment of cancer
|
|
WO2020180959A1
(en)
|
2019-03-05 |
2020-09-10 |
Incyte Corporation |
Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
|
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
|
US11793802B2
(en)
|
2019-03-20 |
2023-10-24 |
Sumitomo Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (AML) with venetoclax failure
|
|
CA3133460A1
(en)
|
2019-03-22 |
2020-10-01 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Compositions comprising pkm2 modulators and methods of treatment using the same
|
|
WO2020205560A1
(en)
|
2019-03-29 |
2020-10-08 |
Incyte Corporation |
Sulfonylamide compounds as cdk2 inhibitors
|
|
TW202102543A
(zh)
|
2019-03-29 |
2021-01-16 |
美商安進公司 |
溶瘤病毒在癌症新輔助療法中之用途
|
|
WO2020223121A1
(en)
|
2019-04-30 |
2020-11-05 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
|
|
WO2020223558A1
(en)
|
2019-05-01 |
2020-11-05 |
Incyte Corporation |
Tricyclic amine compounds as cdk2 inhibitors
|
|
US11440914B2
(en)
|
2019-05-01 |
2022-09-13 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
|
IL287801A
(en)
|
2019-05-07 |
2022-07-01 |
Immunicom Inc |
Increasing responses to checkpoint inhibitors by extracorporeal apheresis
|
|
KR20220016155A
(ko)
|
2019-05-30 |
2022-02-08 |
브리스톨-마이어스 스큅 컴퍼니 |
면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법
|
|
EP3977132A1
(en)
|
2019-05-30 |
2022-04-06 |
Bristol-Myers Squibb Company |
Cell localization signature and combination therapy
|
|
JP2022534967A
(ja)
|
2019-05-30 |
2022-08-04 |
ブリストル－マイヤーズ スクイブ カンパニー |
多腫瘍遺伝子シグネチャーおよびその使用
|
|
JP2022539248A
(ja)
|
2019-07-02 |
2022-09-07 |
フレッド ハッチンソン キャンサー リサーチ センター |
組換えａｄ３５ベクター及び関連遺伝子治療改善
|
|
JP2022539208A
(ja)
|
2019-07-03 |
2022-09-07 |
スミトモ ファーマ オンコロジー， インコーポレイテッド |
チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤およびその使用
|
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
|
TW202115024A
(zh)
|
2019-08-14 |
2021-04-16 |
美商英塞特公司 |
作為cdk2 抑制劑之咪唑基嘧啶基胺化合物
|
|
CN114423786A
(zh)
|
2019-09-16 |
2022-04-29 |
诺华股份有限公司 |
高亲和力的、配体阻断性、人源化的抗T细胞免疫球蛋白结构域和粘蛋白结构域3（TIM-3）IgG4抗体用于治疗骨髓纤维化的用途
|
|
US20220348651A1
(en)
|
2019-09-18 |
2022-11-03 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
|
WO2021067217A1
(en)
|
2019-09-30 |
2021-04-08 |
Incyte Corporation |
Pyrido[3,2-d]pyrimidine compounds as immunomodulators
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
AU2020364007A1
(en)
|
2019-10-11 |
2022-04-28 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
|
TWI891666B
(zh)
|
2019-10-14 |
2025-08-01 |
美商英塞特公司 |
作為ｆｇｆｒ抑制劑之雙環雜環
|
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
CN114786679A
(zh)
|
2019-10-21 |
2022-07-22 |
诺华股份有限公司 |
具有维奈托克和tim-3抑制剂的组合疗法
|
|
TW202128191A
(zh)
|
2019-10-21 |
2021-08-01 |
瑞士商諾華公司 |
Tim-3抑制劑及其用途
|
|
JP2022554346A
(ja)
|
2019-11-05 |
2022-12-28 |
セルジーン コーポレーション |
２－（４－クロロフェニル）－ｎ－（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－イル）メチル）－２，２－ジフルオロアセトアミドとの併用療法
|
|
BR112022009031A2
(pt)
|
2019-11-11 |
2022-10-11 |
Incyte Corp |
Sais e formas cristalinas de um inibidor de pd-1/pd-l1
|
|
IL292924A
(en)
|
2019-11-26 |
2022-07-01 |
Novartis Ag |
Chimeric antigen receptors cd19 and cd22 and their uses
|
|
BR112022010664A2
(pt)
|
2019-12-04 |
2022-08-16 |
Incyte Corp |
Derivados de um inibidor de fgfr
|
|
EP4069696A1
(en)
|
2019-12-04 |
2022-10-12 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
MX2022007759A
(es)
|
2019-12-20 |
2022-07-19 |
Novartis Ag |
Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico.
|
|
MX2022008208A
(es)
|
2020-01-03 |
2022-10-21 |
Incyte Corp |
Terapia de combinación que comprende inhibidores de a2a/a2b y proteína de muerte programada 1 /ligando de muerte programada 1 (pd-1/pdl1).
|
|
EP4090674A4
(en)
|
2020-01-14 |
2024-01-24 |
Synthekine, Inc. |
Biased il2 muteins methods and compositions
|
|
WO2021146424A1
(en)
|
2020-01-15 |
2021-07-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
JP2023510393A
(ja)
|
2020-01-17 |
2023-03-13 |
ノバルティス アーゲー |
骨髄異形成症候群または慢性骨髄単球性白血病の処置に使用するためのｔｉｍ－３阻害剤と低メチル化剤とを含む組合せ
|
|
EP4114401A1
(en)
|
2020-03-06 |
2023-01-11 |
Incyte Corporation |
Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
|
|
US20230093147A1
(en)
|
2020-03-09 |
2023-03-23 |
President And Fellows Of Harvard College |
Methods and compositions relating to improved combination therapies
|
|
KR20230009386A
(ko)
|
2020-04-10 |
2023-01-17 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Ｂ-세포 성숙 항원을 표적화하는 키메라 항원 수용체로 조작된 세포 요법 관련 방법 및 용도
|
|
CA3179692A1
(en)
|
2020-04-16 |
2021-10-21 |
Incyte Corporation |
Fused tricyclic kras inhibitors
|
|
KR20230004726A
(ko)
*
|
2020-04-22 |
2023-01-06 |
아케소 바이오파마, 인크. |
항-cd73/항-pd-1 이중특이항체 및 이의 용도
|
|
US11739102B2
(en)
|
2020-05-13 |
2023-08-29 |
Incyte Corporation |
Fused pyrimidine compounds as KRAS inhibitors
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
EP4157923A2
(en)
|
2020-05-29 |
2023-04-05 |
President And Fellows Of Harvard College |
Living cells engineered with polyphenol-functionalized biologically active nanocomplexes
|
|
AR122644A1
(es)
|
2020-06-19 |
2022-09-28 |
Onxeo |
Nuevas moléculas de ácido nucleico conjugado y sus usos
|
|
CN115916199A
(zh)
|
2020-06-23 |
2023-04-04 |
诺华股份有限公司 |
包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
|
|
US20230293530A1
(en)
|
2020-06-24 |
2023-09-21 |
Yeda Research And Development Co. Ltd. |
Agents for sensitizing solid tumors to treatment
|
|
WO2021262969A1
(en)
|
2020-06-24 |
2021-12-30 |
The General Hospital Corporation |
Materials and methods of treating cancer
|
|
CN115916191A
(zh)
|
2020-06-25 |
2023-04-04 |
新基公司 |
用组合疗法治疗癌症的方法
|
|
CN115997123A
(zh)
|
2020-06-30 |
2023-04-21 |
国家医疗保健研究所 |
用于预测实体癌患者在术前辅助治疗后复发和/或死亡风险的方法
|
|
JP7741831B2
(ja)
|
2020-06-30 |
2025-09-18 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
術前補助療法及び根治手術後の固形がんを患っている患者の再発及び／又は死亡のリスクを予測するための方法
|
|
MX2023000197A
(es)
|
2020-07-07 |
2023-02-22 |
BioNTech SE |
Arn terapeutico para el cancer positivo para vph.
|
|
US12472176B2
(en)
|
2020-07-07 |
2025-11-18 |
Celgene Corporation |
Pharmaceutical compositions comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same
|
|
US20230271940A1
(en)
|
2020-08-03 |
2023-08-31 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
CA3192204A1
(en)
|
2020-08-19 |
2022-02-24 |
Xencor, Inc. |
Anti-cd28 and/or anti-b7h3 compositions
|
|
US11999752B2
(en)
|
2020-08-28 |
2024-06-04 |
Incyte Corporation |
Vinyl imidazole compounds as inhibitors of KRAS
|
|
AU2021334361A1
(en)
|
2020-08-31 |
2023-05-11 |
Bristol-Myers Squibb Company |
Cell localization signature and immunotherapy
|
|
US20230338587A1
(en)
|
2020-08-31 |
2023-10-26 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
US20230321285A1
(en)
|
2020-08-31 |
2023-10-12 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
JP2023542490A
(ja)
|
2020-09-03 |
2023-10-10 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｐｄ－１阻害剤を投与することによりがん疼痛を処置する方法
|
|
WO2022072783A1
(en)
|
2020-10-02 |
2022-04-07 |
Incyte Corporation |
Bicyclic dione compounds as inhibitors of kras
|
|
WO2022099075A1
(en)
|
2020-11-06 |
2022-05-12 |
Incyte Corporation |
Crystalline form of a pd-1/pd-l1 inhibitor
|
|
US11866434B2
(en)
|
2020-11-06 |
2024-01-09 |
Incyte Corporation |
Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
|
|
US11780836B2
(en)
|
2020-11-06 |
2023-10-10 |
Incyte Corporation |
Process of preparing a PD-1/PD-L1 inhibitor
|
|
US20240025993A1
(en)
|
2020-11-06 |
2024-01-25 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
|
IL302402A
(en)
|
2020-11-08 |
2023-06-01 |
Seagen Inc |
Combined treatment
|
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Ａｌｋ﹘５抑制劑和彼之用途
|
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性ｒｎａ
|
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
|
SMT202500208T1
(it)
|
2020-12-28 |
2025-07-22 |
Bristol Myers Squibb Co |
Composizioni anticorpali e metodi per il loro uso
|
|
JP2024501029A
(ja)
|
2020-12-28 |
2024-01-10 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与
|
|
MX2023007850A
(es)
|
2020-12-29 |
2023-09-11 |
Incyte Corp |
Terapia combinada que comprende inhibidores de adora2a/adora2b (a2a/a2b), inhibidores de muerte programada/ligando 1 de muerte programada (pd-1/pd-l1) y anticuerpos de cumulo de diferenciacion 73 (anti-cd73).
|
|
WO2022150788A2
(en)
|
2021-01-11 |
2022-07-14 |
Synthekine, Inc. |
Compositions and methods related to receptor pairing
|
|
TW202241508A
(zh)
|
2021-01-29 |
2022-11-01 |
美商艾歐凡斯生物治療公司 |
細胞介素相關之腫瘤浸潤性淋巴球組合物及方法
|
|
WO2022171121A1
(zh)
|
2021-02-10 |
2022-08-18 |
同润生物医药(上海)有限公司 |
治疗肿瘤的方法和组合
|
|
JP2024511319A
(ja)
|
2021-03-09 |
2024-03-13 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体
|
|
JP2024509274A
(ja)
|
2021-03-10 |
2024-02-29 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
|
|
CN118459539B
(zh)
|
2021-03-19 |
2026-01-06 |
生物治疗探索股份有限公司 |
用于调节训练免疫的化合物及其使用方法
|
|
TW202304506A
(zh)
|
2021-03-25 |
2023-02-01 |
日商安斯泰來製藥公司 |
涉及抗claudin 18.2抗體的組合治療以治療癌症
|
|
JP2024514530A
(ja)
|
2021-04-02 |
2024-04-02 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
切断型ｃｄｃｐ１に対する抗体およびその使用
|
|
US20250319183A1
(en)
|
2021-04-07 |
2025-10-16 |
David Avigan |
Compositions and methods for the treatment of cancer
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
MX2023011796A
(es)
|
2021-04-09 |
2024-01-08 |
Seagen Inc |
Métodos de tratamiento del cáncer con anticuerpos inmunorreceptor de células t con dominios ig e itim (anti-tigit).
|
|
TW202304459A
(zh)
|
2021-04-12 |
2023-02-01 |
美商英塞特公司 |
包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
|
|
EP4323356A1
(en)
|
2021-04-13 |
2024-02-21 |
Nuvalent, Inc. |
Amino-substituted heterocycles for treating cancers with egfr mutations
|
|
AU2022262600A1
(en)
|
2021-04-20 |
2023-10-05 |
Seagen Inc. |
Modulation of antibody-dependent cellular cytotoxicity
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
TW202307210A
(zh)
|
2021-06-01 |
2023-02-16 |
瑞士商諾華公司 |
Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途
|
|
WO2022261159A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
EP4352059A1
(en)
|
2021-06-09 |
2024-04-17 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
US11981671B2
(en)
|
2021-06-21 |
2024-05-14 |
Incyte Corporation |
Bicyclic pyrazolyl amines as CDK2 inhibitors
|
|
MX2024000357A
(es)
|
2021-07-07 |
2024-02-12 |
Incyte Corp |
Compuestos triciclicos como inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras).
|
|
JP2024525758A
(ja)
|
2021-07-13 |
2024-07-12 |
ビオンテック・ソシエタス・エウロパエア |
がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤
|
|
US12600717B2
(en)
|
2021-07-14 |
2026-04-14 |
Incyte Corporation |
Tricyclic compounds as inhibitors of KRAS
|
|
CA3226163A1
(en)
|
2021-07-14 |
2023-01-19 |
Synthekine, Inc. |
Methods and compositions for use in cell therapy of neoplastic disease
|
|
US12441742B2
(en)
|
2021-08-31 |
2025-10-14 |
Incyte Corporation |
Naphthyridine compounds as inhibitors of KRAS
|
|
WO2023049697A1
(en)
|
2021-09-21 |
2023-03-30 |
Incyte Corporation |
Hetero-tricyclic compounds as inhibitors of kras
|
|
WO2023051926A1
(en)
|
2021-09-30 |
2023-04-06 |
BioNTech SE |
Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
|
|
CA3234375A1
(en)
|
2021-10-01 |
2023-04-06 |
Incyte Corporation |
Pyrazoloquinoline kras inhibitors
|
|
US20250002600A1
(en)
|
2021-10-06 |
2025-01-02 |
Genmab A/S |
Multispecific binding agents against pd-l1 and cd137 in combination therapy
|
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
|
WO2023064857A1
(en)
|
2021-10-14 |
2023-04-20 |
Incyte Corporation |
Quinoline compounds as inhibitors of kras
|
|
WO2023083439A1
(en)
|
2021-11-09 |
2023-05-19 |
BioNTech SE |
Tlr7 agonist and combinations for cancer treatment
|
|
WO2023091746A1
(en)
|
2021-11-22 |
2023-05-25 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a kras inhibitor
|
|
TW202329937A
(zh)
|
2021-12-03 |
2023-08-01 |
美商英塞特公司 |
雙環胺ｃｋ１２抑制劑
|
|
US11976073B2
(en)
|
2021-12-10 |
2024-05-07 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
|
WO2023107705A1
(en)
|
2021-12-10 |
2023-06-15 |
Incyte Corporation |
Bicyclic amines as cdk12 inhibitors
|
|
JP2025500922A
(ja)
|
2021-12-16 |
2025-01-15 |
ヴァレリオ・セラピューティクス |
新規のコンジュゲートされた核酸分子及びその使用
|
|
CA3244187A1
(en)
|
2021-12-22 |
2023-06-29 |
Incyte Corporation |
SALTS AND SOLID FORMS OF AN FGFR INHIBITOR AND THEIR METHODS OF PREPARATION
|
|
WO2023147488A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
|
EP4490151A1
(en)
|
2022-03-07 |
2025-01-15 |
Incyte Corporation |
Solid forms, salts, and processes of preparation of a cdk2 inhibitor
|
|
EP4493575A1
(en)
|
2022-03-18 |
2025-01-22 |
Bristol-Myers Squibb Company |
Methods of isolating polypeptides
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
TW202413412A
(zh)
|
2022-05-12 |
2024-04-01 |
丹麥商珍美寶股份有限公司 |
在組合療法中能夠結合到ｃｄ２７之結合劑
|
|
EP4532010A1
(en)
|
2022-05-27 |
2025-04-09 |
Takeda Pharmaceutical Company Limited |
Dosing of cd38-binding fusion protein
|
|
EP4531916A1
(en)
|
2022-06-02 |
2025-04-09 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
|
PE20250927A1
(es)
|
2022-06-08 |
2025-04-02 |
Incyte Corp |
Compuestos triciclicos de triazolo como inhibidores de dgk
|
|
AR129675A1
(es)
|
2022-06-22 |
2024-09-18 |
Incyte Corp |
Inhibidores de cdk12 de aminas biciclicas
|
|
EP4543923A1
(en)
|
2022-06-22 |
2025-04-30 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|
|
WO2024015731A1
(en)
|
2022-07-11 |
2024-01-18 |
Incyte Corporation |
Fused tricyclic compounds as inhibitors of kras g12v mutants
|
|
US12600722B2
(en)
|
2022-07-18 |
2026-04-14 |
Incyte Corporation |
Tetracyclic compounds as DGK inhibitors
|
|
US12600723B2
(en)
|
2022-07-18 |
2026-04-14 |
Incyte Corporation |
Tetracyclic compounds as DGK inhibitors
|
|
CA3263560A1
(en)
|
2022-08-05 |
2024-02-08 |
Juno Therapeutics, Inc. |
GPRC5D AND BCMA SPECIFIC CHIMERICAL ANTIGENIC RECEPTORS
|
|
EP4604939A1
(en)
|
2022-10-20 |
2025-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination therapy for the treatment of cancer
|
|
AR131099A1
(es)
|
2022-11-18 |
2025-02-19 |
Incyte Corp |
Fluoroalquenos heteroarílicos como inhibidores de dgk
|
|
JP2025541738A
(ja)
|
2022-12-01 |
2025-12-23 |
ビオンテック・ソシエタス・エウロパエア |
抗ｐｄ１ａｂと化学療法での併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性抗体
|
|
CN120712102A
(zh)
|
2022-12-13 |
2025-09-26 |
朱诺治疗学股份有限公司 |
对baff-r和cd19具特异性的嵌合抗原受体及其方法和用途
|
|
KR20250120305A
(ko)
|
2022-12-14 |
2025-08-08 |
아스텔라스 파마 유럽 비.브이. |
Cldn18.2 및 cd3에 결합하는 2중 특이성 결합제와 면역 체크포인트 저해제를 수반한 조합 요법
|
|
AR131101A1
(es)
|
2023-01-12 |
2025-02-19 |
Incyte Corp |
Heteroarilfluoroalquenos como inhibidores de dgk
|
|
JP2026505276A
(ja)
|
2023-01-31 |
2026-02-13 |
ユニバーシティ オブ ロチェスター |
Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ感染症を治療するための免疫チェックポイント遮断療法
|
|
CN121620391A
(zh)
|
2023-04-06 |
2026-03-06 |
金麦安博股份有限公司 |
用于治疗癌症的针对pd-l1和cd137的多特异性结合剂
|
|
WO2024220532A1
(en)
|
2023-04-18 |
2024-10-24 |
Incyte Corporation |
Pyrrolidine kras inhibitors
|
|
GEAP202616866A
(en)
|
2023-04-18 |
2026-02-10 |
Incyte Corp |
2-azabicyclo[2.2.1]heptane kras inhibitors
|
|
CN121285385A
(zh)
|
2023-05-12 |
2026-01-06 |
金麦安博股份有限公司 |
能够与ox40结合的抗体、其变体及其用途
|
|
WO2024254245A1
(en)
|
2023-06-09 |
2024-12-12 |
Incyte Corporation |
Bicyclic amines as cdk2 inhibitors
|
|
CN121712571A
(zh)
|
2023-08-15 |
2026-03-20 |
百时美施贵宝公司 |
陶瓷羟基磷灰石色谱流通法
|
|
WO2025043151A2
(en)
|
2023-08-24 |
2025-02-27 |
Incyte Corporation |
Bicyclic dgk inhibitors
|
|
WO2025056180A1
(en)
|
2023-09-15 |
2025-03-20 |
BioNTech SE |
Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
|
|
WO2025068452A1
(en)
|
2023-09-29 |
2025-04-03 |
Negio Therapeutics |
Guanfacine derivatives and their use in treating cancer
|
|
WO2025068461A1
(en)
|
2023-09-29 |
2025-04-03 |
Negio Therapeutics |
Guanfacine derivatives and their use in treating cancer
|
|
AU2024357850A1
(en)
|
2023-10-09 |
2026-04-23 |
Incyte Corporation |
Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
|
|
TW202515903A
(zh)
|
2023-10-12 |
2025-04-16 |
瑞士商百濟神州瑞士有限責任公司 |
手術前後基於抗ｐｄ－１之治療
|
|
US20250163079A1
(en)
|
2023-11-01 |
2025-05-22 |
Incyte Corporation |
Kras inhibitors
|
|
TW202540189A
(zh)
|
2023-11-30 |
2025-10-16 |
德商生物新技術公司 |
在組合療法中能夠結合ｏｘ４０之抗體
|
|
TW202523667A
(zh)
|
2023-12-05 |
2025-06-16 |
美商英塞特公司 |
作為ｄｇｋ抑制劑之三環三唑并化合物
|
|
US20250186450A1
(en)
|
2023-12-06 |
2025-06-12 |
Incyte Corporation |
COMBINATION THERAPY COMPRISING DGK INHIBITORS and PD-1/PD-L1 INHIBITORS
|
|
WO2025120867A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
|
|
AR134560A1
(es)
|
2023-12-08 |
2026-01-28 |
Astellas Pharma Inc |
Terapia de combinación que implica agentes de unión biespecíficos que se unen a cldn18.2 y cd3 y agentes que estabilizan o aumentan la expresión de cldn18.2
|
|
WO2025120866A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2026033885A1
(en)
|
2024-08-08 |
2026-02-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
US20250195536A1
(en)
|
2023-12-13 |
2025-06-19 |
Incyte Corporation |
Bicyclooctane kras inhibitors
|
|
WO2025132831A1
(en)
|
2023-12-19 |
2025-06-26 |
Universite D'aix-Marseille |
N-heteroaryl derivatives and uses thereof for treating cancer
|
|
WO2025145207A1
(en)
|
2023-12-29 |
2025-07-03 |
Bristol-Myers Squibb Company |
Combination therapy of kras inhibitor and treg-depleting agent
|
|
WO2025153834A1
(en)
|
2024-01-19 |
2025-07-24 |
Institut National de la Santé et de la Recherche Médicale |
Methods of predicting the risk of recurrence and/or death of patients suffering from a hepatocellular carcinoma (hcc)
|
|
TW202545567A
(zh)
|
2024-01-30 |
2025-12-01 |
美商思進公司 |
抗ｐｄ－ｌ１抗體和抗體－藥物共軛體及彼等在治療癌症的用途
|
|
WO2025202213A1
(en)
|
2024-03-26 |
2025-10-02 |
Institut National de la Santé et de la Recherche Médicale |
Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells
|
|
WO2025219595A1
(en)
|
2024-04-19 |
2025-10-23 |
Biper Therapeutics |
Method for combination treatments using alkynylbenzenesulphonamides for cancer therapy
|
|
WO2025252855A1
(en)
|
2024-06-05 |
2025-12-11 |
Institut National de la Santé et de la Recherche Médicale |
IL-15 MUTEINS WITH PH-DEPENDENT BINDING FOR IL-15Rbeta
|
|
WO2025252857A1
(en)
|
2024-06-05 |
2025-12-11 |
Institut National de la Santé et de la Recherche Médicale |
Il-15 muteins with ph-dependent binding for il-15ralpha
|
|
WO2025262250A1
(en)
|
2024-06-20 |
2025-12-26 |
Negio Therapeutics |
Guanfacine derivatives and their uses
|
|
WO2026060143A1
(en)
|
2024-09-11 |
2026-03-19 |
Incyte Corporation |
Kras inhibitors
|
|
WO2026076207A1
(en)
|
2024-10-04 |
2026-04-09 |
Incyte Corporation |
Tricyclic heteroaryl compounds as inhibitors of tyk2 and/or jak1
|